David R. Liu, a biologist at the Broad Institute and Harvard, is the lead author of a new study of a gene-editing strategy that could be standardized for multiple people with rare diseases.
At an international conference, researchers at the forefront of animal-human transplantation compared notes and allowed themselves the first real optimism in decades.
Login
